Diabetes Act
Latest Action
Read twice and referred to the Committee on Finance.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Diabetes Act (S.5502) is a Senate bill introduced in the 118th Congress focused on health policy related to diabetes. The bill was read twice and referred to the Senate Committee on Finance on December 12, 2024. However, the bill ultimately failed or expired without further legislative action. No official summary or full text of the bill is publicly available, limiting detailed analysis of its specific provisions or objectives.
S.5502, the Diabetes Act, was introduced but did not advance beyond committee referral and ultimately expired without enactment, with no detailed public information on its content.
- The bill was introduced in the Senate during the 118th Congress and referred to the Committee on Finance.
- No official summary or full text is available, so the specific policy measures or funding mechanisms are unknown.
- The bill is categorized under the health policy area and relates to diabetes, a significant public health concern.
['People living with diabetes', 'Healthcare providers specializing in diabetes care', 'Public health agencies focused on chronic disease management', 'Potentially pharmaceutical and medical device industries related to diabetes treatment']
['Lack of publicly available text and summary limits understanding of implementation requirements and costs.', 'Unclear authority and oversight provisions due to absence of detailed bill language.', 'Potential policy tradeoffs cannot be assessed without knowledge of specific provisions.']
The bill was introduced in the Senate and referred to the Committee on Finance, a key committee for health-related legislation involving funding and Medicare/Medicaid programs. The failure or expiration of the bill indicates it did not progress through the legislative process during the 118th Congress. The absence of a summary or text suggests limited public disclosure or documentation of the bill's content.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could have influenced healthcare funding priorities related to diabetes care and prevention.', 'Potential changes in insurance coverage or public health programs might have affected access to diabetes treatments.', 'Pharmaceutical and medical device markets related to diabetes management could have experienced regulatory or funding shifts.']
The absence of an official summary and full bill text significantly limits transparency and public oversight. This lack of information restricts the ability of stakeholders to analyze the bill's provisions, assess fiscal impacts, or understand enforcement mechanisms. The bill's failure to advance beyond committee referral further reduces opportunities for public scrutiny or amendment.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.